These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
10. A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. de Wilde AH; Wannee KF; Scholte FE; Goeman JJ; Ten Dijke P; Snijder EJ; Kikkert M; van Hemert MJ J Virol; 2015 Aug; 89(16):8318-33. PubMed ID: 26041291 [TBL] [Abstract][Full Text] [Related]
11. Human coronavirus dependency on host heat shock protein 90 reveals an antiviral target. Li C; Chu H; Liu X; Chiu MC; Zhao X; Wang D; Wei Y; Hou Y; Shuai H; Cai J; Chan JF; Zhou J; Yuen KY Emerg Microbes Infect; 2020 Dec; 9(1):2663-2672. PubMed ID: 33179566 [TBL] [Abstract][Full Text] [Related]
12. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. Fattahi S; Khalifehzadeh-Esfahani Z; Mohammad-Rezaei M; Mafi S; Jafarinia M Immunol Res; 2022 Jun; 70(3):269-275. PubMed ID: 35107743 [TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG mBio; 2020 Sep; 11(5):. PubMed ID: 32913009 [TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses. Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219 [TBL] [Abstract][Full Text] [Related]
15. Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection. Comar CE; Goldstein SA; Li Y; Yount B; Baric RS; Weiss SR mBio; 2019 Mar; 10(2):. PubMed ID: 30914508 [TBL] [Abstract][Full Text] [Related]
16. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. de Wilde AH; Jochmans D; Posthuma CC; Zevenhoven-Dobbe JC; van Nieuwkoop S; Bestebroer TM; van den Hoogen BG; Neyts J; Snijder EJ Antimicrob Agents Chemother; 2014 Aug; 58(8):4875-84. PubMed ID: 24841269 [TBL] [Abstract][Full Text] [Related]
17. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326 [TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
19. A Novel Frameshifting Inhibitor Having Antiviral Activity against Zoonotic Coronaviruses. Ahn DG; Yoon GY; Lee S; Ku KB; Kim C; Kim KD; Kwon YC; Kim GW; Kim BT; Kim SJ Viruses; 2021 Aug; 13(8):. PubMed ID: 34452503 [TBL] [Abstract][Full Text] [Related]
20. An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery. Kandeel M Expert Opin Drug Discov; 2023 Apr; 18(4):385-400. PubMed ID: 36971501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]